This session provided both advice on providing clinical care and tips on the subtleties of terminology when interacting with trans & nonbinary or gender diverse patients.
What You Need to Know About COVID-19 & Therapies for Rheumatic Diseases
PHILADELPHIA—Since March 2020, the world has been turned upside down by the COVID-19 pandemic. Rheumatologists must understand how to best protect and treat their patients with autoimmune conditions at risk for infection due to immunosuppressive therapy. At ACR Convergence 2022, the session titled, Latest COVID and Rheumatic Disease Therapies: What You Need to Know, provided…
Patients Living with Chronic Illness
At ACR Convergence 2022, three women with rheumatic diseases discuss the profound life changes that the diseases wrought and ways they’ve found to cope.
Rheumatic Disease Research in Indigenous Populations
This ACR Convergence 2022 session focused on ways to improve health equity in Indigenous populations.
The ACR Thanks 2022 RheumPAC Matching Campaign Donors
The ACR is grateful to all members who donated to RheumPAC during this year’s matching campaign, which raised over $27,000 from members and another $13,000 from volunteer leaders who made a pledge for each donor.
Evolution of Medicare’s Merit-Based Incentive Payment System: MIPS Value Pathways
In November, the CMS finalized 12 MIPS Value Pathways (MVP) in the Quality Payment Program, including a rheumatology MVP. In 2023, clinicians can opt to report via traditional MIPS, the rheumatology MVP or both.
Understaffed, Over-Scrutinized & Feeling Powerless? ACR Advocacy Can Help
Elizabeth “Blair” Solow, MD, MSc, and Angus Worthing, MD, FACP, FACR, described the top political issues affecting rheumatology now and how ACR members can work toward practices and policies that help us better care for patients.
Considering Benzbromarone as First-Line Therapy for Gout
In this comparative effectiveness clinical trial, Yan et al. set out to compare nontitrated, low-dose benzbromarone (not approved in the U.S.), a renal urate transporter 1 inhibitor, with low-dose febuxostat as the first-line therapy in gout patients with renal uric acid underexcretion.
Challenges in Psoriatic Arthritis
PHILADELPHIA—Despite a large and ever-growing number of therapeutic options for our patients with psoriatic disease, it is not uncommon for us come across scenarios in which a patient’s response to therapy does not match our expectations and our shared goals for treatment. We all have those patients—the ones whose joints improve with one drug, but…
Advocacy Involvement ‘An Antidote to Burnout,’ Says New Government Affairs Chair Christina Downey, MD
The new chair of the ACR’s Government Affairs Committee, Dr. Downey says physicians play a vital role in helping policymakers understand how policies and laws affect patients and the practice of rheumatology.
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 308
- Next Page »